HORIZON

PIVOTAL STUDY

  • Ongoing phase 2 study in 157 patients
  • RRMM patients with few or no remaining treatment options
  • Patients have received >2 earlier lines of therapy with IMiDs and PIs and are refractory to pomalidomide and/or daratumumab
  • Submission process in the US for accelerated approval for melflufen underway
  • Started in Q1 2017, data reporting in 2018/2019 and follow-up 2019/2020